Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of oral FPF300 for recurrent epistaxis in hereditary hemorrhagic telangiectasia
jRCT2051200141Phase 2Completed
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topiroxostat in hereditary hemorrhagic telangiectasia (HHT), sponsored by Fujimoto Pharmaceutical. Primary endpoint: Improvement rate of Epistaxis Severity Score. Started Mar 2021; status: completed.
02
Drugs
topiroxostat
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on jRCT2051200141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200141.